Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$27100.00
-450.00 (-1.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $7.4B · quality 40.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$315.8B
P/E
N/A
•EV/EBITDA
5.3x
↓ROE
11.4%
↑Gross Margin
45.5%
↓Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.0%
FCF CAGR
—
FCF margin
3.3%
FCF / Net income
0.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $620.77B · net income $42.66B · FCF $20.69B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $620.77B | $620.77B | $590.23B | $552.01B | $492.39B |
| Net Income | $42.66B | $42.66B | $29.45B | $50.47B | $22.44B |
| EBITDA | $81.97B | $81.97B | $62.20B | $83.84B | $60.15B |
| EPS | — | — | 2374.00 | 4120.00 | 1897.00 |
| Gross Margin | 45.5% | 45.5% | 48.3% | 51.8% | 54.4% |
| Operating Margin | 7.3% | 7.3% | 6.7% | 10.1% | 8.3% |
| Net Margin | 6.9% | 6.9% | 5.0% | 9.1% | 4.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.52 | 0.38 | 0.37 |
| Current Ratio | 1.51 | 1.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $20.69B | $20.69B | $-31.65B | $7.38B | $-10.69B |
| Returns | |||||
| ROE | 11.4% | 11.4% | 8.5% | 15.5% | 7.9% |
| Valuation | |||||
| P/E | — | — | 11.33 | 9.24 | 15.45 |
| EV/EBITDA | 5.34 | 5.34 | 7.37 | 6.25 | 7.00 |
| P/B | 0.84 | 0.84 | 0.96 | 1.43 | 1.23 |
| Growth & Yield | |||||
| Revenue Growth | 5.2% | 5.2% | 6.9% | 12.1% | — |
| EPS Growth | — | — | -42.4% | 117.2% | — |
| Dividend Yield | 4.1% | 4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.9%
Start / end P/E
n/dx → n/dx
EPS bridge
2374.00 → n/d
Residual
-3.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.